In contrast, KRAS G12R tumors contained more niches where T cells and tumor cells coexisted, correlating with better clinical prognosis.[39] This observation suggested that KRAS G12D may hinder antitumor immunity by restricting effective interactions between CD8+ T cells and tumor cells. The gene discussed is KRAS; the disease is neoplasm.